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Metabolic Syndrome and Health-related 
Quality of Life in Obese Individuals Seeking 
Weight Reduction 
Adam Gilden Tsai1, Thomas A. Wadden1, David B. Sarwer1, Robert I. Berkowitz1, Leslie G. Womble1, 
Louise A. Hesson1, Suzanne Phelan2 and Rebecca Rothman1 
background: No previous research has examined the association between metabolic syndrome (MetSyn) and 
health-related quality of life (HRQoL) using standard criteria for defining MetSyn. We hypothesized that MetSyn would 
be associated with lower HRQoL on measures of physical and mental health. 
Methods and Procedures: Participants were 361 individuals in two randomized weight loss trials. MetSyn was 
defined by the National Cholesterol Education Panel criteria. The Medical Outcomes Study, Short Form-36 (SF-36) 
was used to assess HRQoL. Differences in HRQoL and in clinical and psychosocial characteristics were compared 
among participants with and without MetSyn. Multiple regression was used to determine predictors of HRQoL. 
Results: MetSyn was associated with lower scores on the physical function and general health subscales of the 
SF-36 and on the physical component summary (PCS) score. This association remained after controlling for age or 
depression but was eliminated by controlling for BMI. MetSyn was not associated with lower mental quality of life, a 
higher depression score, tobacco or alcohol use, or a higher rate of psychosocial stressors. 
Discussion: Individuals with MetSyn reported lower HRQoL. This appeared to be an effect of increased weight, rather 
than a unique effect of MetSyn. Larger studies are needed to assess whether MetSyn may have an independent 
effect on HRQoL. 
IntroductIon Health Organization (10,11). In addition, these studies did 
Metabolic syndrome (MetSyn) is associated with an increased not examine whether differences in quality of life that were 
risk for developing type 2 diabetes, as well as cardiovascular attributed to MetSyn may, in fact, have been attributable to the 
disease (1–3). Insulin resistance is thought to lie at the heart higher BMI of persons with the syndrome. 
of the syndrome, which is diagnosed when patients meet at In the present study, we used the Medical Outcomes Study,
least three of the following five criteria: elevated waist circum- Short Form-36 (SF-36) (12,13) to determine whether individ­
ference (>40 inches for men, >35 inches for women); high uals with metabolic syndrome had lower scores on the physi­
triglycerides (>150 mg/dl); reduced high-density lipoprotein cal health and mental health subscales of the instrument. The 
cholesterol (<40 mg/dl for men, <50 mg/dl for women); high physical health subscales include those that measure physical 
fasting glucose (>100 mg/dl); and elevated blood pressure function (i.e., degree of limitation in performing activities of
(>130/85 mm Hg) (4). daily living), physical role (i.e., limitations in daily activi-
Some investigators believe that metabolic syndrome is also ties due to physical health), bodily pain (i.e., limitations in
associated with an increased risk for psychiatric comorbidity, daily activities due to pain), and general health (i.e., self-
stress, and impaired health-related quality of life (HRQoL) evaluation of overall health). The mental health subscales
(5–8). For example, two previous studies have reported that include those that measure vitality (i.e., energy and fatigue), 
individuals with metabolic syndrome had a reduced quality of social functioning (i.e., limitations in social activities due
life, principally in the area of physical function (7,9). In these to physical or emotional health), emotional role (i.e., limi­
two studies, however, unconventional criteria were used to tations in usual role activities due to emotional problems),
define MetSyn, as compared to the criteria developed by the and general mental health (i.e., psychological distress and
National Cholesterol Education Program (4) or by the World well-being). We also examined whether the hypothesized
1Center for Weight and Eating Disorders, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; 2Weight Control and Diabetes Research 
Center, The Miriam Hospital, Brown Medical School, Providence, Rhode Island, USA.
 
  
      
 
 
  
 
 
    
           
          
        
 
          
         
            
 
 
           
          
 
            
 
           
 
 
 
        
  
  
 
 
   
 
   
  
  
  
       
 
  
        
       
     
 
 
 
  
 
 
 
 
 
 
 
association between MetSyn and lower HRQoL could be
explained, in part, by a higher BMI or by a higher rate of psy­
chosocial complications (e.g., depression, history of mental 
illness, alcohol and tobacco abuse, and stress) among those
with the syndrome. 
Methods And procedures 
participants 
Participants were 404 overweight and obese individuals who took 
part in one of two randomized weight control trials that have been 
reported previously (14,15). Participants in both studies were required 
to have a BMI of 30–45 kg/m2 and were excluded if they had signifi­
cant medical or psychiatric comorbidities, described previously (15). 
These included uncontrolled hypertension (>140/90 mm Hg), types 
1 or 2 diabetes, or the use of medications known to cause long-term 
changes in weight. The presence of MetSyn was assessed using the 
National Cholesterol Education Program criteria (4). Participants 
who took medications for hypertension or hypercholesterolemia were 
counted as meeting the blood pressure and triglyceride criteria for 
metabolic syndrome. 
outcomes measures 
SF-36. The SF-36 was used to assess HRQoL. This measure includes 
eight subscales, all of which are used to derive a summary measure 
of physical health and a summary measure of mental health (12,13). 
Higher scores, both on the eight subscales and the two summary mea­
sures, indicate better functioning. 
Depression. Symptoms of depression were assessed using the Beck 
Depression Inventory (BDI-II), the standard measure for depression in
mental health (16). Scores range from 0 to 63, with higher values indic­
ative of greater symptoms of depression. Scores of 0–13 are considered 
minimal (i.e., in the normal range). Participants also reported whether 
they had a history of mental health problems, as assessed by the Weight 
and Lifestyle Inventory (17). 
Lifestyle habits. Lifestyle habits, including smoking and alcohol 
intake, were also assessed with the Weight and Lifestyle Inventory 
(17). This questionnaire has good reliability for these items (18). The 
Weight and Lifestyle Inventory was also used to identify ongoing 
sources of stress, including those related to work, intimate relation­
ships, and legal/financial troubles. Participants responded yes or no 
to the presence of each of eight psychosocial stressors, as described 
previously (17). 
statistical analysis 
Full data concerning MetSyn and quality of life were available for 361 
of the original 404 participants. Individuals who were not included in 
the analysis data set did not differ in age, weight, BMI, education, or
ethnicity from the 361 persons for whom full data were available. If a 
participant had missing data on one or more components of MetSyn
but met at least three criteria, the individual was designated as having 
the syndrome. 
Differences in weight and in other characteristics between participants
with and without MetSyn were compared using t-tests for continuous
variables and chi-square tests for categorical variables. Similar analyses 
were used to compare individuals with and without MetSyn on: (i) the
eight subscales of the SF-36; (ii) symptoms of depression; (iii) lifestyle
habits; and (iv) psychosocial stressors. 
Zero-order correlations were used to estimate the strength of asso­
ciation between HRQoL and single variables of interest. Multivariable
regression was then used to assess the total variance in HRQoL explained
by all predictor variables. All analyses were conducted using Stata soft­
ware, version 9.2 (Stata Corporation, College Station, TX). A P value
<0.05 was considered significant for all analyses. 
results 
Metabolic syndrome 
Participants with MetSyn had a significantly greater age (P = 
0.002), height (P < 0.001), weight (P < 0.001), and BMI (P < 
0.001) than those without the syndrome (Table 1). A higher
percentage of individuals with MetSyn were white (P = 0.02)
and male (P < 0.001). As expected, participants with MetSyn
also had significantly higher blood pressure, higher fasting 
glucose and insulin, higher triglycerides, and lower high-den­
sity lipoprotein cholesterol than did those without MetSyn
(P < 0.001 for all comparisons). Low-density lipoprotein
cholesterol levels did not differ significantly between the two 
groups (Table 1). 
Quality of life 
Comparisons of HRQoL between participants with and with­
out MetSyn are shown in Table 2. Individuals with MetSyn had 
significantly lower scores on two of the eight subscales of the 
table 1 Baseline characteristics of participants with and 
without metabolic syndrome, among individuals seeking 
weight reductiona 
No metabolic Metabolic 
syndrome syndrome 
(n = 226) (n = 135) P value 
Gender, number (%) 
Female 190 (84.1%) 82 (60.7%) <0.001 
Male 36 (15.9%) 53 (39.3%) 
Ethnicity 
White 167 (73.9%) 113 (83.7%) 0.02 
African American 56 (24.8%) 20 (14.8%) 
Otherb 3 (1.3%) 2 (1.5%) 
Age (year) 44.9 ± 10.0 48.2 ± 9.5 0.002 
Education (year) 15.6 ± 2.3 15.7 ± 2.3 0.67 
Weight (kg) 96.7 ± 18.4 109.0 ± 18.6 <0.001 
Height (cm) 166.6 ± 7.7 170.4 ± 10.1 <0.001 
BMI (kg/m2) 34.7 ± 5.6 37.4 ± 4.2 <0.001 
Waist (cm) 41.5 ± 5.4 45.0 ± 5.1 <0.001 
Low-density 123.2 ± 30.7 121.5 ± 33.6 0.61 
lipoprotein (mg/dl) 
High-density 61.2 ± 13.7 46.8 ± 11.0 <0.001 
lipoprotein (mg/dl) 
Triglycerides (mg/dl) 104.3 ± 48.0 184.6 ± 123.0 <0.001 
Systolic blood 123.1 ± 14.6 137.3 ± 14.5 <0.001 
pressure (mm Hg) 
Diastolic blood 68.7 ± 9.8 74.2 ± 10.0 <0.001 
pressure (mm Hg) 
Glucose (mg/dl) 91.4 ± 9.1 101.2 ± 15.0 <0.001 
Insulin (μU/ml) 12.9 ± 8.1 21.3 ± 15.8 <0.001 
Insulin resistancec 2.9 ± 2.0 5.5 ± 4.9 <0.001 
aValues are mean ± s.d. with the exception of gender and ethnicity, which are 
shown as n (%). bOther = Asian–American or Latino. cInsulin resistance was deter­
mined using the homeostasis model of insulin resistance (26). Scores range from 
0 to 15, with higher scores indicating greater insulin resistance, and are calcu­
lated as the product of the fasting plasma insulin level (in microunits per milliliter) 
and the fasting plasma glucose level (in millimoles/liter), divided by 22.5. 
 
 
 
 
  
        
        
 
 
 
  
  
 
          
 
           
      
 
 
 
  
 
 
  
      
 
 
 
 
  
 
 
   
   
  
        
 
 
  
         
      
 
 
 
 
  
 
 
 
 
 
SF-36. These were, physical functioning (P = 0.021) and gen- Depression Inventory scores or in the percentage of patients 
eral health (P = 0.007). Participants with MetSyn also scored who reported a history of mental health problems or of alco­
significantly lower on the physical component summary (PCS) hol or tobacco use. There also were no significant differences
score (P = 0.013). No differences were observed between those between groups in the number of psychosocial stressors
with and without MetSyn on any of the four subscales of the (Table 3). 
SF-36 that assessed dimensions of mental health or in the men­
tal component summary score (Table 2). correlations and regression analyses 
Correlation and regression analyses are shown in Tables 4 
psychosocial status and lifestyle habits and 5 for the PCS score of the SF-36. In univariable analy-
The psychosocial characteristics of participants with and ses, lower values on the PCS score were associated with the
without MetSyn are shown in Table 3. No significant dif- presence of MetSyn, higher BMI values and depression scores, 
ferences were observed between the two groups in Beck and with higher age. By contrast, there was no association
between the PCS score and years of education, gender, ethnic-
table 2 Baseline sF-36 scores for participants with and ity, alcohol intake, smoking status, or psychosocial stressors
without metabolic syndrome among individuals seeking (Table 4).
weight reductiona A forward step-wise regression analysis was conducted 
No metabolic Metabolic using the four variables that had the strongest association 
syndrome syndrome with the PCS score derived from univariable analysis. They 
(n = 226) (n = 135) P value 
Physical functioning 80.6 ± 18.1 75.9 ± 19.5 0.021 table 4 univariable correlation of the physical component
Role physical 82.2 ± 30.7 77.6 ± 34.2 0.19 summary (pcs) score of the sF-36 with demographic and 
psychosocial variables Bodily pain 72.8 ± 21.8 72.7 ± 20.6 0.99 
Correlation 
Variable coefficient P value 
General health 71.3 ± 16.9 66.3 ± 17.7 0.007 
Vitality 49.6 ± 18.4 50.5 ± 18.7 0.68 
BMI −0.27 <0.001 
Social function 85.4 ± 19.0 83.5 ± 20.5 0.38 
Depression scorea −0.23 <0.001 
Role emotional 75.5 ± 36.1 80.0 ± 34.6 0.25 
Metabolic syndrome −0.15 0.004 
Mental health 74.7 ± 15.3 75.1 ± 14.6 0.80 
Age −0.15 0.005 
Physical component 49.1 ± 8.4 46.8 ± 8.4 0.013 
summary Years of education	 0.1 0.07 
Ever smoker −0.08 0.11
 
summary
 
Mental component 48.6 ± 9.7 49.9 ± 9.2 0.23 
Drinks per week −0.07 0.21
 
SF-36, Medical Outcomes Study, Short Form-36.
 Number of stressors 0.03 0.52 
aValues are mean ± s.d.
 
Ethnicity 0.04 0.53
 
Gender	 0.02 0.69table 3 psychosocial characteristics and lifestyle habits of
participants with and without metabolic syndrome among 	 SF-36, Medical Outcomes Study, Short Form-36.
 
aBeck Depression Inventory.
 individuals seeking weight reductiona 
No metabolic Metabolic 

syndromeb syndromec P value
 table 5 Variance in the physical component summary (pcs)
Beck Depression Inventory 7.7 ± 6.8 7.7 ± 7.2 0.96 score accounted for by BMI, depression score, age, and the 
metabolic syndrome, as determined by forward step-wise History of mental health 58 (26.0%) 33 (24.8%) 0.80
 
problems, number (%) regression
 
Psychosocial stressors, 1.6 ± 1.4 1.4 ± 1.3 0.21 Variable Cumulative R2 P value 
total number Full model 
Work, number (%) 116 (51.8%) 65 (48.9%) 0.59 BMI	 0.07 <0.001 
Health, number (%) 57 (25.4%) 32 (24.1%) 0.77 Depression scorea 0.11 <0.001 
Intimate relationships, 49 (21.9%) 20 (15.0%) 0.11 Age	 0.15 <0.001 
number (%) Metabolic syndrome 0.15 0.63 
Legal/financial, number (%) 53 (23.7%) 25 (18.8%) 0.28
 
Partial model #1
 
Current smoker, number (%) 9 (4.0%) 4 (3.0%) 0.77 BMI	 0.07 <0.001 
Ever smoker, number (%) 106 (47.3%) 69 (51.9%) 0.41	 Age 0.10 0.001 
Metabolic syndrome 0.10 0.52 
Alcoholic drinks per week, 2.3 ± 3.9 3.0 ± 4.7 0.11
 
number
 Partial model #2 
BMI 0.07 <0.001 
aValues are mean ± s.d. for depression score, number of stressors, and drinks Metabolic syndrome 0.07 0.19
per week; and n (%) for other variables. bn ranges from 219 to 224. cn ranges 

from 131 to 133. aBeck Depression Inventory.
 
  
         
 
   
 
 
          
        
 
  
       
 
 
 
         
 
 
 
 
 
      
          
 
  
 
  
 
  
 
  
  
 
 
 
  
 
  
  
 
 
  
 
  
 
  
 
 
  
  
 
  
 
 
  
   
   
 
   
 
were entered into the regression according to the strength of 
their association—BMI, depression score, age, and MetSyn. As 
shown in Table 5, three variables—BMI, depression score, and 
age—explained 15% of the variance in the PCS score. MetSyn 
did not contribute significantly to the variance explained 
after accounting for these three variables. Secondary analyses 
showed that the effect of MetSyn was eliminated by controlling 
for BMI alone (Table 5). 
dIscussIon 
This study found that MetSyn was associated with lower 
HRQoL on two of the physical subscales of the SF-36. These 
were physical function (i.e., limitations in daily activities due 
to physical health) and general health (i.e, self-reported over­
all health status). In addition, participants with MetSyn scored 
significantly lower on the PCS score than did persons with­
out the syndrome. By contrast, no association was observed 
between MetSyn and the mental component summary score or 
any of the SF-36 subscales related to mental health. There also 
was no association between MetSyn and symptoms of depres­
sion, alcohol or tobacco use, or psychosocial stressors. 
Participants in the present study who had MetSyn had a 
significantly higher BMI than those without the syndrome
(37.4 kg/m2 vs. 34.7 kg/m2, respectively). Correlation analy­
ses showed that both BMI and MetSyn were associated with
a lower PCS score. Results of multiple regression analysis,
however, showed that MetSyn did not account for a signifi­
cant amount of the variance in PCS scores after controlling for 
BMI. Thus, the reduced HRQoL in participants with MetSyn 
appeared to be related to their greater BMI, rather than to
MetSyn per se. Numerous studies have shown that a higher
BMI is associated with lower HRQoL (19–25). 
Two previous studies reported that MetSyn was associated 
with reduced HRQoL (7,9). However, neither of these inves­
tigations controlled for the effect of BMI. In addition, neither
of these studies used standardized criteria to define MetSyn,
such as the criteria used by the National Cholesterol Education
Panel (4) or World Health Organization (10,11). A third study 
found lower SF-36 scores at baseline for all eight domains
among a population of surgically treated obese patients, but
no association of lower quality of life with insulin resistance
(19). The other criteria for MetSyn were not examined. 
The present study had several limitations. First, patients with 
type 2 diabetes were excluded from both of the clinical trials 
used for the analysis. Obese individuals with type 2 diabetes 
are likely to meet the criteria for MetSyn and may experience 
lower HRQoL than persons with the syndrome who do not have 
diabetes. Second, our sample consisted principally of persons 
from middle- to upper-middle socioeconomic backgrounds 
(mean education of 15.6 years in the present analysis). Higher 
socioeconomic status may protect obese individuals from the 
potential adverse health and psychosocial consequences of 
MetSyn. Third, we failed to observe the expected relationship 
between psychosocial stress and MetSyn. This may have been 
attributable to our use of a suboptimal measure to detect stress. 
Future studies should correct this limitation. 
In summary, the present study found that excess weight 
appeared to explain the decrease in HRQoL observed in par­
ticipants with MetSyn. Larger studies of more diverse samples 
are needed to confirm this finding. 
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